| Initial genome sequencing and analysis of multiple myeloma MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ... Nature 471 (7339), 467-472, 2011 | 1734 | 2011 |
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ... Cancer cell 25 (1), 91-101, 2014 | 1120 | 2014 |
| Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ... The Lancet 387 (10027), 1551-1560, 2016 | 996 | 2016 |
| Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma RI Fisher, SH Bernstein, BS Kahl, B Djulbegovic, MJ Robertson, S De Vos, ... Journal of clinical oncology 24 (30), 4867-4874, 2006 | 885 | 2006 |
| Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome JA Coppell, PG Richardson, R Soiffer, PL Martin, NA Kernan, A Chen, ... Biology of blood and marrow transplantation 16 (2), 157-168, 2010 | 686 | 2010 |
| RNA-based gene therapy for HIV with lentiviral vector–modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma DL DiGiusto, A Krishnan, L Li, H Li, S Li, A Rao, S Mi, P Yam, S Stinson, ... Science translational medicine 2 (36), 36ra43-36ra43, 2010 | 516 | 2010 |
| Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, ... Blood 130 (8), 974-981, 2017 | 501 | 2017 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, E Kastritis, E Terpos, P Sonneveld, N Leung, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 453 | 2016 |
| Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study A Goy, SH Bernstein, BS Kahl, B Djulbegovic, MJ Robertson, S De Vos, ... Annals of oncology 20 (3), 520-525, 2009 | 425 | 2009 |
| Solid cancers after bone marrow transplantation S Bhatia, AD Louie, R Bhatia, MR O’Donnell, H Fung, A Kashyap, ... Journal of Clinical Oncology 19 (2), 464-471, 2001 | 361 | 2001 |
| Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors A Krishnan, S Bhatia, ML Slovak, DA Arber, JC Niland, A Nademanee, ... Blood, The Journal of the American Society of Hematology 95 (5), 1588-1593, 2000 | 348 | 2000 |
| Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102 … A Krishnan, MC Pasquini, B Logan, EA Stadtmauer, DH Vesole, ... The lancet oncology 12 (13), 1195-1203, 2011 | 341 | 2011 |
| Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population PG Richardson, AD Elias, A Krishnan, C Wheeler, R Nath, ... Blood, The Journal of the American Society of Hematology 92 (3), 737-744, 1998 | 327 | 1998 |
| Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure PG Richardson, ML Riches, NA Kernan, JA Brochstein, S Mineishi, ... Blood 127 (13), 1656-1665, 2016 | 302 | 2016 |
| Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial PG Richardson, RJ Soiffer, JH Antin, H Uno, Z Jin, J Kurtzberg, PL Martin, ... Biology of Blood and Marrow Transplantation 16 (7), 1005-1017, 2010 | 271 | 2010 |
| Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial EA Stadtmauer, MC Pasquini, B Blackwell, P Hari, A Bashey, S Devine, ... Journal of Clinical Oncology 37 (7), 589, 2019 | 259 | 2019 |
| A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in … A Nademanee, S Forman, A Molina, H Fung, D Smith, A Dagis, C Kwok, ... Blood 106 (8), 2896-2902, 2005 | 249 | 2005 |
| Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas A Krishnan, A Molina, J Zaia, D Smith, D Vasquez, N Kogut, PM Falk, ... Blood 105 (2), 874-878, 2005 | 224 | 2005 |
| American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and … S Giralt, L Garderet, B Durie, G Cook, G Gahrton, B Bruno, P Hari, ... Biology of Blood and Marrow Transplantation 21 (12), 2039-2051, 2015 | 208 | 2015 |
| Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma A Krishnan, A Nademanee, HC Fung, AA Raubitschek, A Molina, ... Journal of Clinical Oncology 26 (1), 90-95, 2008 | 199 | 2008 |
